Clinical Trial Update: A Study of GC101 TIL in Advanced Melanoma (10hospital) [EARLY_Phase 1]

View source ↗

Summary

An early-phase study evaluating GC101 Tumor Infiltrating Lymphocytes (TIL) for advanced melanoma is listed as recruiting, sponsored by Shanghai Juncell Therapeu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• GC101 TIL

Snippet

Sponsor: Shanghai Juncell Therapeutics | Conditions: Advanced Melanoma, Tumor Infiltrating Lymphocyte | EARLY_Phase 1 | Status: RECRUITING